|
US4466977A
(en)
|
1981-04-09 |
1984-08-21 |
The Upjohn Company |
N-[2-Amino(oxy- or thia- group-substituted-cycloaliphatic)]benzeneacetamides and -benzamide analgesics
|
|
US4438130A
(en)
|
1981-11-12 |
1984-03-20 |
The Upjohn Company |
Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
|
|
US4463013A
(en)
|
1982-04-09 |
1984-07-31 |
The Upjohn Company |
Oxygen substituted amino-cyclohexyl-benzeneacetamides and -benzamides as water diuretic drugs
|
|
US4656182A
(en)
|
1983-12-06 |
1987-04-07 |
Warner-Lambert Company |
Substituted trans-1,2-diaminocyclohexyl amide compounds
|
|
US4588591A
(en)
|
1984-05-25 |
1986-05-13 |
The Upjohn Company |
Analgesic 2-oxa-spirocyclic compounds
|
|
US4632935A
(en)
|
1984-05-30 |
1986-12-30 |
The Upjohn Company |
Omega-(hydroxy-, ether and ester)-alkyl-2-amino-cycloalkyl- and cycloalkenyl amides as analgesics
|
|
US4618621A
(en)
|
1984-09-21 |
1986-10-21 |
The Upjohn Company |
Method for treating medical conditions involving cerebral ischemia
|
|
US4677122A
(en)
|
1984-11-13 |
1987-06-30 |
Warner-Lambert Company |
Substituted trans-1,2-diaminocyclohexyl amide compounds
|
|
US4737493A
(en)
|
1985-07-01 |
1988-04-12 |
Warner-Lambert Company |
7-((substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro(4,5)decanes as analgesic agents
|
|
US4801604A
(en)
|
1985-10-25 |
1989-01-31 |
The Upjohn Company |
Cis-N-(2-aminocycloaliphatic)benzamide anti-convulsants
|
|
US4855316A
(en)
|
1988-02-18 |
1989-08-08 |
Warner-Lambert Company |
1,2-diamino-4,5-dimethoxycyclohexyl amide analgesic compounds
|
|
US5051428A
(en)
|
1988-12-06 |
1991-09-24 |
Warner-Lambert Company |
2-amino-4 or 5-methoxycyclohexyl amides useful as analgesics
|
|
US5063242A
(en)
|
1989-04-21 |
1991-11-05 |
Warner-Lambert Company |
7-((substituted)amino)-8-((substituted)carbonyl)-methylamino-1-oxaspiro[4,5]decanes as diuretics antiinflammatory, and cerebrovascular agents
|
|
US5366987A
(en)
|
1991-08-22 |
1994-11-22 |
Warner-Lambert Company |
Isoxazolyl-substituted alkyl amide ACAT inhibitors
|
|
GB9420557D0
(en)
*
|
1994-10-12 |
1994-11-30 |
Zeneca Ltd |
Aromatic compounds
|
|
MX9706394A
(es)
*
|
1995-02-22 |
1997-11-29 |
Novartis Ag |
Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina, especialmente neuroquinina-1.
|
|
FR2734815B1
(fr)
|
1995-05-31 |
1997-07-04 |
Adir |
Nouveaux composes arylalkyl (thio) carboxamides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US6127159A
(en)
|
1997-06-06 |
2000-10-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Mitofusin genes and their uses
|
|
AU8003400A
(en)
|
1999-10-06 |
2001-05-10 |
Ansgar H. Santel |
Mitofusins, fzo homologs and functional derivatives thereof
|
|
AU2003303042A1
(en)
|
2002-12-17 |
2004-07-09 |
Pfizer Inc. |
2-pyridyl and 2-pyrimidyl cycloalkylene amide compounds as nr2b receptor antagonists
|
|
JP4675330B2
(ja)
|
2003-11-14 |
2011-04-20 |
デューク ユニバーシティ |
シャルコー・マリー・ツース病２ａ型の検出方法
|
|
JP2007186422A
(ja)
|
2004-01-28 |
2007-07-26 |
Astellas Pharma Inc |
アリールスルフィド誘導体
|
|
JP2008517072A
(ja)
|
2004-10-20 |
2008-05-22 |
ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア |
可溶性エポキシド加水分解酵素の改良された阻害剤
|
|
US8354094B1
(en)
|
2005-01-04 |
2013-01-15 |
Gp Medical, Inc. |
Pharmaceutical composition of nanoparticles
|
|
US8361439B1
(en)
|
2005-01-04 |
2013-01-29 |
Gp Medical, Inc. |
Pharmaceutical composition of nanoparticles
|
|
US8791069B1
(en)
|
2005-01-04 |
2014-07-29 |
Gp Medical, Inc. |
Pharmaceutical composition of nanoparticles
|
|
US8226928B1
(en)
|
2011-06-17 |
2012-07-24 |
Gp Medical, Inc. |
Pharmaceutical composition of nanoparticles
|
|
US8574544B1
(en)
|
2005-01-04 |
2013-11-05 |
Gp Medical, Inc. |
Pharmaceutical composition of nanoparticles
|
|
CA2663254C
(en)
|
2006-09-15 |
2016-04-19 |
Reviva Pharmaceuticals, Inc. |
Synthesis, methods of using, and compositions of cycloalkylmethylamines
|
|
US20100047177A1
(en)
|
2007-01-26 |
2010-02-25 |
Washington University |
Methods and compositions for treating neuropathies
|
|
JP2011501731A
(ja)
|
2007-09-10 |
2011-01-13 |
ユニバーシティ オブ マサチューセッツ |
ミトコンドリア標的化抗腫瘍剤
|
|
WO2009114700A2
(en)
|
2008-03-12 |
2009-09-17 |
The Trustees Of Columbia University In The City Of New York |
Cell model of neurodegenerative disease and methods of use thereof for identifying inhibitors of mitochondrial fusion
|
|
US9212155B2
(en)
|
2008-03-19 |
2015-12-15 |
Aurimmed Pharma, Inc. |
Compounds advantageous in the treatment of central nervous system diseases and disorders
|
|
US20110256565A1
(en)
|
2008-05-30 |
2011-10-20 |
Schon Eric A |
Methods for diagnosis and treatment of neurodegenerative diseases or disorders
|
|
US20110275670A1
(en)
|
2008-06-04 |
2011-11-10 |
Emma Chapman |
New Compounds VII
|
|
WO2011053825A2
(en)
|
2009-10-30 |
2011-05-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for the treatment or prevention of mitochondrial diseases
|
|
WO2011133879A2
(en)
|
2010-04-22 |
2011-10-27 |
University Of Massachusetts |
Combination therapies with mitochondrial-targeted anti-tumor agents
|
|
WO2012003501A2
(en)
|
2010-07-02 |
2012-01-05 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
|
|
PH12022550598A1
(en)
|
2010-12-23 |
2024-03-11 |
Amazentis Sa |
Compositions and methods for improving mitochondrial function and treating neurodenegenerative diseases and cognitive disorders
|
|
WO2012114204A2
(en)
|
2011-02-15 |
2012-08-30 |
Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto |
Methods of treating mitochondrial dysfunction
|
|
WO2012158624A2
(en)
|
2011-05-13 |
2012-11-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibitors of mitochondrial fission and methods of use thereof
|
|
WO2013010003A1
(en)
|
2011-07-12 |
2013-01-17 |
University Of Medicine And Dentistry Of New Jersey |
Diagnostic biomarker profiles for the detection and diagnosis of alzheimer's disease
|
|
US9238625B2
(en)
|
2011-12-30 |
2016-01-19 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
|
|
WO2013123305A1
(en)
|
2012-02-16 |
2013-08-22 |
The Penn State Research Foundation |
Modulators of acyl-coa lysocardiolipin acyltransferase 1 ( alcat1) and uses thereof
|
|
HRP20170532T4
(hr)
|
2012-07-12 |
2019-12-27 |
Khondrion Ip B.V. |
Derivati kromanila za liječenje mitohondrijske bolesti
|
|
US20160030517A1
(en)
|
2012-10-10 |
2016-02-04 |
University Of Washington Through Its Center For Commercialization |
Compositions and methods for diagnosis and treatment of neurological disease
|
|
US9603890B2
(en)
|
2012-12-03 |
2017-03-28 |
Vascular Biosciences |
Methods for increasing the selective efficacy of gene therapy using CAR peptide and heparan-sulfate mediated macropinocytosis
|
|
WO2014124458A1
(en)
|
2013-02-11 |
2014-08-14 |
The Regents Of The University Of California |
Compositions and methods for treating neurodegenerative diseases
|
|
EP3043810B1
(en)
|
2013-09-09 |
2019-10-23 |
CanImGuide Therapeutics AB |
Immune system modulators
|
|
US20150168379A1
(en)
|
2013-12-12 |
2015-06-18 |
Macau University Of Science And Technology |
Method of identifying and screening drug candidate for preventing and/or treating ischemic myocardial disease
|
|
CN106061497A
(zh)
|
2013-12-20 |
2016-10-26 |
曼尼托巴大学 |
用于治疗周围神经病变的方法和组合物
|
|
EP3108257B1
(en)
|
2014-02-17 |
2019-10-30 |
Société des Produits Nestlé S.A. |
Methods and uses of mitofusins
|
|
WO2015142001A2
(ko)
*
|
2014-03-21 |
2015-09-24 |
충남대학교산학협력단 |
강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
|
|
JP6659571B2
(ja)
|
2014-04-16 |
2020-03-04 |
ノーザン・シドニー・ローカル・ヘルス・ディストリクト |
神経変性障害の治療又は予防のための細胞内Ｎｉｘ介在性マイトファジーを増大させる剤及び方法並びにキット
|
|
US10059748B2
(en)
|
2014-06-10 |
2018-08-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Pharmaceutical compositions for prevention or treatment of neurodegenerative diseases
|
|
US20180085391A1
(en)
|
2014-08-08 |
2018-03-29 |
Modernatx, Inc. |
Compositions and methods for the treatment of ophthalmic diseases and conditions
|
|
CA2958585C
(en)
|
2014-08-21 |
2024-01-09 |
Stealth Biotherapeutics Corp |
Use of peptide d-arg-2',6'-dmt-lys-phe-nh2 for the treatment of alport syndrome
|
|
WO2016054083A1
(en)
|
2014-09-30 |
2016-04-07 |
The Trustees Of Columbia University In The City Of New York |
Methods and pharmaceutical compositions for treatment of amyotrophic lateral sclerosis
|
|
US9865522B2
(en)
|
2014-11-18 |
2018-01-09 |
International Business Machines Corporation |
Composite heat sink structures
|
|
KR101647030B1
(ko)
|
2014-11-20 |
2016-08-09 |
한국생명공학연구원 |
미토푸신 억제제를 포함하는, 세포 리프로그래밍 촉진용 조성물 및 이의 용도
|
|
WO2016115632A1
(en)
|
2015-01-21 |
2016-07-28 |
Exerkine Corporation |
Method for treating mitochondrial disease
|
|
WO2016126707A1
(en)
|
2015-02-03 |
2016-08-11 |
Lam Therapeutics, Inc. |
Apilimod compositions and methods for using same
|
|
US10143719B2
(en)
|
2015-02-06 |
2018-12-04 |
Case Western Reserve University |
Inhibitors of valosin-containing protein and methods of use
|
|
WO2016161294A1
(en)
|
2015-04-02 |
2016-10-06 |
Salk Institute For Biological Studies |
Err alpha and err gamma are essential coordinators of cardiac metabolism and function
|
|
WO2016205193A1
(en)
|
2015-06-15 |
2016-12-22 |
Rush Unversity Medical Center |
BRAIN DERIVED PPARα LIGANDS
|
|
WO2017009650A1
(en)
|
2015-07-14 |
2017-01-19 |
Mission Therapeutics Limited |
Cyanopyrrolidines as dub inhibitors for the treatment of cancer
|
|
US10815211B2
(en)
|
2015-10-08 |
2020-10-27 |
Khondrion Ip B.V. |
Compounds for treating mitochondrial disease
|
|
CN108476164B
(zh)
|
2015-12-21 |
2021-10-08 |
谷歌有限责任公司 |
在消息传送应用中自动地提供机器人服务的方法
|
|
GB201602854D0
(en)
|
2016-02-18 |
2016-04-06 |
Mission Therapeutics Ltd |
Novel compounds
|
|
WO2018013811A1
(en)
|
2016-07-14 |
2018-01-18 |
The Regents Of The University Of California |
Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders
|
|
US11401255B2
(en)
|
2016-07-28 |
2022-08-02 |
Mayo Foundation For Medical Education And Research |
Small molecule activators of Parkin enzyme function
|
|
CN110214183A
(zh)
|
2016-08-03 |
2019-09-06 |
哈佛大学的校长及成员们 |
腺苷核碱基编辑器及其用途
|
|
KR101872105B1
(ko)
|
2016-09-05 |
2018-06-27 |
사회복지법인 삼성생명공익재단 |
샤르코 마리 투스병 치료용 약학 조성물
|
|
WO2018057648A1
(en)
|
2016-09-20 |
2018-03-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Peptide regulators of mitochondrial fusion and methods of use
|
|
WO2018098484A1
(en)
|
2016-11-28 |
2018-05-31 |
Texas Tech University System |
Drug targets of delayed aging and human brain diseases
|
|
EP3548039B1
(en)
|
2016-12-04 |
2023-07-19 |
Alavi Khorassani Moghadam, Marcel Victor |
Ribavirin for use in the treatment of a mitochondrial disease
|
|
CN120136858A
(zh)
|
2017-03-31 |
2025-06-13 |
中美博瑞纳制药有限公司 |
可用作alcat1抑制剂的化合物
|
|
US20200054718A1
(en)
|
2017-04-05 |
2020-02-20 |
Lara S Milane |
EGFR/MFN2 Targeted Nanoparticles Particularly Useful For Treating Multidrug Resistant Triple Negative Breast Cancer Through Mitochondrial Fusion Inhibition
|
|
WO2018200323A1
(en)
|
2017-04-23 |
2018-11-01 |
Washington University |
Small molecule regulators of mitochondrial fusion and methods of use thereof
|
|
GB201708652D0
(en)
|
2017-05-31 |
2017-07-12 |
Mission Therapeutics Ltd |
Novel compounds and uses
|
|
US20210128596A1
(en)
|
2017-09-27 |
2021-05-06 |
University Of Pennsylvania |
Compositions and methods for treating septic cardiomyopathy
|
|
EP3692169B1
(en)
|
2017-10-06 |
2023-08-16 |
Universiteit Antwerpen |
Biomarkers for charcot-marie-tooth type 2 disease
|
|
WO2019079243A1
(en)
|
2017-10-17 |
2019-04-25 |
Albert Einstein College Of Medicine, Inc. |
MITOFUSIN ACTIVATORS AND USES THEREOF
|
|
US10660873B2
(en)
|
2018-02-23 |
2020-05-26 |
University Of South Florida |
ALDA-1 treatment and prevention of pulmonary disease
|
|
CA3097840A1
(en)
|
2018-04-20 |
2019-10-24 |
Fondazione Telethon |
Mir-181 inhibitors and uses thereof
|
|
EP3575401A1
(en)
|
2018-05-29 |
2019-12-04 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Methods of treating or preventing an aging-related disease
|
|
EP3801515B1
(en)
|
2018-06-06 |
2025-04-09 |
Minoryx Therapeutics S.L. |
5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
|
|
WO2020030954A1
(en)
|
2018-08-09 |
2020-02-13 |
Integrative Medicine Clinic, Sia |
Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
|
|
WO2020112565A1
(en)
|
2018-11-29 |
2020-06-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonists of mitofusion 1 and beta ii pkc association for treating heart failure
|
|
JP7734917B2
(ja)
*
|
2019-01-28 |
2025-09-08 |
ミトコンドリア エモーション， インク． |
トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
|
|
AU2019427489B2
(en)
|
2019-01-28 |
2025-03-13 |
Mitochondria Emotion, Inc. |
Mitofusin activators and methods of use thereof
|